Invasive Fungal Infections in Acute Promyelocytic Leukemia on Dual Differentiating Agents: Real World Data

Area of Science:

• Hematology
• Infectious Diseases
• Oncology

Background:

• Invasive fungal infections (IFIs) pose a significant threat to patients with acute promyelocytic leukemia (APL), particularly in developing countries.
• The efficacy of dual differentiating agents, arsenic trioxide (ATO) and all-trans retinoic acid (ATRA), in managing APL and their impact on IFI incidence require further investigation.

Purpose of the Study:

• To determine the incidence of IFIs in APL patients treated with dual differentiating agents (ATO and ATRA) in a systematic Indian trial (DID-IT).
• To analyze the factors influencing IFI occurrence in APL patients undergoing this specific therapy.

Main Methods:

• A systematic study (DID-IT) was conducted on 98 APL patients.
• Patients received dual differentiating agents (ATO and ATRA).
• Incidence and classification of IFIs were recorded.

Main Results:

• An 18.3% incidence of IFIs was observed in the 98 APL patients (18 cases).
• Among the IFIs, 3 were definitive, 14 were probable, and 1 was possible.
• The study identified environmental and therapy-related factors influencing IFI incidence.

Conclusions:

• The incidence of IFIs in APL patients is influenced by environmental and therapy-related factors.
• The use of dual differentiating agents (ATO and ATRA) alone does not necessarily reduce the occurrence of fungal infections in APL.
• Further research is needed to understand and mitigate IFI risks in APL patients.